「ag」の検索結果
47件：26～30件目を表示
-
quarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a TRPV1 antagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: To...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117_0.pdf -
March 7, 2025 General Announcement Senju Pharmaceutical Co., Ltd. Announcement of Licensing Agreement with Brill International Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr...
https://www.senju.co.jp/system/files/content_news/2025-03/ENG_20250307_0.pdf -
March 7, 2025 General Announcement Senju Pharmaceutical Co., Ltd. Announcement of Licensing Agreement with Brill International Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr...
https://www.senju.co.jp/system/files/content_news/2025-03/ENG_20250307.pdf -
vative. BAC is widely used in eye drops but it is known to occasionally cause corneal epithelial damage1. Our goal was to develop a formulation that maintains the efficacy of the previous formulation ...
https://www.senju.co.jp/system/files/content_news/2025-09/ENG_20250904.pdf -
产品开发方针 | 研究与开发 | 千寿制药株式会社
f world population. 2024. #4: 横井则彦，加藤弘明：干眼症诊疗范式的变化 眼表面的分层诊断和分层治疗.京府医大期刊，2013 122(8):549-57 #5: Nakagawa T, Tokuda Y, Nakano M, Komori Y, Hanada N, Tourtas T, et al. RNA-Seq-based transcriptome analy...
http://www.senju.co.jp/chinese/rd/policy/